Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
Equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT